Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive | Zendy

Elias Mouchlianitis | Zendy; Michael Bloomfield | Zendy; Vincent Law | Zendy; Katherine Beck | Zendy; Sudhakar Selvaraj | Zendy; Naresh Rasquinha | Zendy; Adam Waldman | Zendy; Federico Turkheimer | Zendy; Alice Egerton | Zendy; James Stone | Zendy; Oliver Howes | Zendy

Open Access

Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive

Author(s) -

Elias Mouchlianitis,

Michael Bloomfield,

Vincent Law,

Katherine Beck,

Sudhakar Selvaraj,

Naresh Rasquinha,

Adam Waldman,

Federico Turkheimer,

Alice Egerton,

James Stone,

Oliver Howes

Publication year - 2015

Publication title -

schizophrenia bulletin

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.823

H-Index - 190

eISSN - 1745-1707

pISSN - 0586-7614

DOI - 10.1093/schbul/sbv151

Subject(s) - glutamatergic , anterior cingulate cortex , schizophrenia (object oriented programming) , glutamate receptor , medicine , antipsychotic , population , psychology , neuroscience , psychiatry , receptor , cognition , environmental health

Resistance to antipsychotic treatment is a significant clinical problem in patients with schizophrenia with approximately 1 in 3 showing limited or no response to repeated treatments with antipsychotic medication. The neurobiological basis for treatment resistance is unknown but recent evidence implicates glutamatergic function in the anterior cingulate cortex. We examined glutamate levels of chronically ill treatment-resistant patients directly compared to treatment-responsive patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research